Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 7/20 | 0.36 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.36 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.36 |
| ▸ | USP5 | P45974 | 1/20 | 0.35 |
| ▸ | MYC | P01106 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | MPO | P05164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21995110 | 1.00 | TLR7 (0.36) | TLR7TLR8NUDT1USP5MYC | |
| SCHEMBL23924725 | 0.91 | TLR7 (0.34) | TLR7TLR8NUDT1USP5MYC | |
| SCHEMBL23924727 | 0.91 | TLR7 (0.34) | TLR7TLR8NUDT1USP5MYC | |
| SCHEMBL23924487 | 0.90 | USP5 (0.34) | TLR7TLR8NUDT1USP5MYC | |
| SCHEMBL23924488 | 0.90 | USP5 (0.34) | TLR7TLR8NUDT1USP5MYC | |
| SCHEMBL29508398 | 0.87 | USP5 (0.39) | TLR7TLR8USP5TSHRMEN1 | |
| SCHEMBL22749271 | 0.85 | USP5 (0.37) | TLR7TLR8USP5TSHR | |
| SCHEMBL22749243 | 0.83 | TLR7 (0.39) | TLR7TLR8USP5TSHR | |
| SCHEMBL29508402 | 0.83 | TLR7 (0.39) | TLR7TLR8USP5TSHR | |
| SCHEMBL22749242 | 0.82 | USP5 (0.40) | TLR7NUDT1USP5TSHRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12540137-B2 | N-1 branched alkyl ether substituted imidazo[4,5-c]quinoline compounds, compositions, and methods | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) | 2026-02-03 | — | — | US | disclosed |
| US-20240300947-A1 | N-1 Branched Alkyl Ether Substituted Imidazo[4,5-c]Quinoline Compounds, Compositions, and Methods | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) | 2024-09-12 | — | — | US | disclosed |
| US-12024514-B2 | N-1 branched alkyl ether substituted imidazo[4,5-c]quinoline compounds, compositions, and methods | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) | 2024-07-02 | — | — | US | disclosed |
| CN-113166143-B | N-1 branched alkyl ether substituted imidazo [4,5-c ] quinoline compounds, compositions and methods | 舒万诺知识产权公司 | 2024-06-04 | — | — | CN | disclosed |
| EP-3887369-B1 | N-1 BRANCHED ALKYL ETHER SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) | 2024-05-08 | — | — | EP | disclosed |
| US-20210323962-A1 | N-1 BRANCHED ALKYL ETHER SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2021-10-21 | — | — | US | disclosed |
| EP-3887369-A1 | N-1 BRANCHED ALKYL ETHER SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS | 3M Innovative Properties Company (US) | 2021-10-06 | — | — | EP | disclosed |
| CN-113166143-A | N-1 branched alkyl ether substituted imidazo [4,5-c ] quinoline compounds, compositions, and methods | 3M创新有限公司 | 2021-07-23 | — | — | CN | disclosed |
| WO-2020109898-A1 | N-1 BRANCHED ALKYL ETHER SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2020-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12540137-B2 | N-1 branched alkyl ether substituted imidazo[4,5-c]quinoline compounds, compositions, and methods | IRF3, IFNAR1, IFNG | TLR7 51/4885TLR8 307/4885NUDT1 3709/4885 |
| US-20240300947-A1 | N-1 Branched Alkyl Ether Substituted Imidazo[4,5-c]Quinoline Compounds, Compositions, and Methods | IFNG, IFNAR1, IRF3 | TLR7 20/4885TLR8 89/4885NUDT1 802/4885 |
| US-20210323962-A1 | N-1 BRANCHED ALKYL ETHER SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS | IFNG, IFNAR1, IRF3 | TLR7 17/4885TLR8 78/4885NUDT1 855/4885 |
| US-12024514-B2 | N-1 branched alkyl ether substituted imidazo[4,5-c]quinoline compounds, compositions, and methods | IFNG, IFNAR1, IRF3 | TLR7 17/4885TLR8 78/4885NUDT1 855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.